Morbidity and mortality after benign prostatic hyperplasia surgery: Data from the American college of surgeons national surgical quality improvement program

Journal of Endourology

Volumn 28, Issue 7, 2014, Pages 831-840

  Bhojani, Naeem ^a   Gandaglia, Giorgio ^a   Sood, Akshay ^b,c   Rai, Arun ^c,d   Pucheril, Daniel ^b   Chang, Steven L ^c   Karakiewicz, Pierre I ^a   Menon, Mani ^b   Olugbade, Kola ^c,e   Ruhotina, Nedim ^c   Sammon, Jesse D ^b   Sukumar, Shyam ^b   Sun, Maxine ^a   Ghani, Khurshid R ^e   Schmid, Marianne ^c   Varda, Briony ^c   Kibel, Adam S ^c   Zorn, Kevin C ^a   Trinh, Quoc Dien ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN;

AGED; AGING; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CAUCASIAN; CLINICAL EVALUATION; COHORT ANALYSIS; DATA BASE; HEALTH PROGRAM; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LASER ENUCLEATION OF THE PROSTATE; LASER VAPORIZATION OF THE PROSTATE; LENGTH OF STAY; LUNG COMPLICATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RACE; RELIABILITY; REOPERATION; RISK; SAFETY; SEPSIS; SHOCK; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION; WOUND COMPLICATION;

AGE FACTORS; AGED; BLOOD TRANSFUSION; DATABASES, FACTUAL; HEMATOCRIT; HUMANS; LASER THERAPY; LENGTH OF STAY; MALE; MORBIDITY; ODDS RATIO; PROSTATIC HYPERPLASIA; QUALITY IMPROVEMENT; REGRESSION ANALYSIS; REOPERATION; SERUM ALBUMIN; SOCIETIES, MEDICAL; TRANSURETHRAL RESECTION OF PROSTATE; UNITED STATES;

EID: 84903751066     PISSN: 08927790     EISSN: 1557900X     Source Type: Journal    
DOI: 10.1089/end.2013.0805     Document Type: Article

References (32)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-471.
2. Berges RR, Pientka L. Management of the BPH syndrome in Germany: Who is treated and how? Eur Urol 1999; 36(suppl 3):21-27.
3. Norman RW, Nickel JC, Fish D, Pickett SN. 'Prostate-related symptoms' in Canadian men 50 years of age or older: Prevalence and relationships among symptoms. Br J Urol 1994;74:542-550.
4. Lee E, Yoo KY, Kim Y, et al. Prevalence of lower urinary tract symptoms in Korean men in a community-based study. Eur Urol 1998;33:17-21.
5. Roghmann F, Ghani KR, Kowalczyk KJ, et al. Incidence and treatment patterns in males presenting with lower urinary tract symptoms to the emergency department in the United States. J Urol 2013;190:1798-1804.
6. Groves HK, Chang D, Palazzi K, et al. The incidence of acute urinary retention secondary to BPH is increasing among California men. Prostate Cancer Prostatic Dis 2013; 16:260-265.
7. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign pros-tatic obstruction. Eur Urol 2013;64:118-140.
8. Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46: 547-554.
9. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)-incidence, management, and prevention. Eur Urol 2006; 50:969-980.
10. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: A prospective multicenter evaluation of 10, 654 patients. J Urol 2008;180:246-249.
11. Herrmann TR, Liatsikos EN, Nagele U, et al. EAU guidelines on laser technologies. Eur Urol 2012;61:783-795.
12. Krambeck AE, Handa SE, and Lingeman JE. Experience with more than 1, 000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol 2013;189:S141-S145.
13. Elmansy HM, Kotb A, Elhilali MM. Holmium laser enu-cleation of the prostate: Long-term durability of clinical outcomes and complication rates during 10 years of fol-lowup. J Urol 2011;186:1972-1976.
14. Andersson SO, Rashidkhani B, Karlberg L, et al. Prevalence of lower urinary tract symptoms in men aged 45-79 years: A population-based study of 40 000 Swedish men. BJU Int 2004;94:327-331.
15. Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: Results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009;104:352-360.
16. Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int 2012;109: 84-87.
17. El-Hakim A, Elhilali MM. Holmium laser enucleation of the prostate can be taught: The first learning experience. BJU Int 2002;90:863-869.
18. Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following transure-thral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010;58:384-397.
19. Alivizatos G, Skolarikos A, Chalikopoulos D, et al. Transurethral photoselective vaporization versus transve-sical open enucleation for prostatic adenomas 80ml: 12-mo results of a randomized prospective study. Eur Urol 2008;54:427-437.
20. Bouchier-Hayes DM, Anderson P, Van Appledorn S, et al. KTP laser versus transurethral resection: Early results of a randomized trial. J Endourol 2006;20:580-585.
21. Cullen DJ, Apolone G, Greenfield S, et al. ASA Physical Status and age predict morbidity after three surgical procedures. Ann Surg 1994;220:3-9.
22. Jeldres C, Isbarn H, Capitanio U, et al. Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia. J Urol 2009;182:626-632.
23. Frierson GM, Howard EN, DeFina LE, et al. Effect of race and socioeconomic status on cardiovascular risk factor burden: The Cooper Center Longitudinal Study. Ethn Dis 2013;23:35-42.
24. Sammon J, Trinh VQ, Ravi P, et al. Health care-associated infections after major cancer surgery: Temporal trends, patterns of care, and effect on mortality. Cancer 2013;119: 2317-2324.
25. Trinh QD, Sun M, Sammon J, et al. Disparities in access to care at high-volume institutions for uro-oncologic procedures. Cancer 2012;118:4421-4426.
26. Goldwasser P. Albumin trend and mortality. Am J Kidney Dis 1997;30:308-309.
27. Goldwasser P, Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997 50:693-703.
28. Lambert JW, Ingham M, Gibbs BB, et al. Using preoper-ative albumin levels as a surrogate marker for outcomes after radical cystectomy for bladder cancer. Urology 2013; 81:587-592.
29. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-619.
30. Bachmann A, Muir GH, Collins EJ, et al. 180-W XPS GreenLight laser therapy for benign prostate hyperplasia: Early safety, efficacy, and perioperative outcome after 201 procedures. Eur Urol 2012;61:600-607.
31. Ben-Zvi T, Hueber PA, Abdollah F, et al. Short term outcomes of GreenLight vapor incision technique (VIT) of the prostate: Comparison of outcomes to standard GreenLight 120W HPS vaporization in prostate volumes greater than 80 cc. Can J Urol 2013;20:6633-6639.
32. Iacono F, Prezioso D, Di Lauro G, et al. Efficacy and safety profile of a novel technique, ThuLEP (Thulium laser enucleation of the prostate) for the treatment of benign prostate hypertrophy. Our experience on 148 patients. BMC Surg 2012;12(suppl 1): S21.